Regeneron Pharmaceuticals, Inc. (0R2M.L)
USD 587.46
(-4.56%)
USD 587.46
(-4.56%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 2.58 Billion USD | 7.44% |
| 2022 | 2.4 Billion USD | 23.09% |
| 2021 | 1.95 Billion USD | 1.81% |
| 2020 | 1.91 Billion USD | 35.4% |
| 2019 | 1.41 Billion USD | 22.96% |
| 2018 | 1.15 Billion USD | 58.54% |
| 2017 | 726.13 Million USD | 81.83% |
| 2016 | 399.35 Million USD | 67.39% |
| 2015 | 238.57 Million USD | 85.14% |
| 2014 | 128.86 Million USD | 83.16% |
| 2013 | 70.35 Million USD | 145.67% |
| 2012 | 28.63 Million USD | 111.26% |
| 2011 | 13.55 Million USD | 189.53% |
| 2010 | -15.14 Million USD | 0.0% |
| 2009 | - USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | 0.0% |
| 2006 | - USD | -100.0% |
| 2005 | 2.9 Million USD | -10.07% |
| 2004 | 3.22 Million USD | -64.15% |
| 2003 | 9 Million USD | 31.84% |
| 2002 | 6.83 Million USD | 71.94% |
| 2001 | 3.97 Million USD | 107.47% |
| 2000 | 1.91 Million USD | -58.37% |
| 1999 | 4.6 Million USD | 0.0% |
| 1998 | - USD | 0.0% |
| 1997 | - USD | 0.0% |
| 1996 | - USD | 0.0% |
| 1995 | - USD | 0.0% |
| 1994 | - USD | 0.0% |
| 1993 | - USD | 0.0% |
| 1992 | - USD | 0.0% |
| 1991 | - USD | 0.0% |
| 1990 | - USD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 2.71 Billion USD | 5.21% |
| 2024 Q3 | 3.01 Billion USD | 5.03% |
| 2024 Q2 | 2.87 Billion USD | 5.85% |
| 2023 Q1 | 1.86 Billion USD | -22.16% |
| 2023 Q2 | 2 Billion USD | 7.41% |
| 2023 FY | 2.58 Billion USD | 7.44% |
| 2023 Q3 | 2.56 Billion USD | 27.58% |
| 2023 Q4 | 2.58 Billion USD | 0.72% |
| 2022 Q2 | 2.21 Billion USD | 11.4% |
| 2022 Q4 | 2.4 Billion USD | -0.43% |
| 2022 FY | 2.4 Billion USD | 23.09% |
| 2022 Q1 | 1.99 Billion USD | 2.06% |
| 2022 Q3 | 2.41 Billion USD | 8.73% |
| 2021 Q3 | 2.05 Billion USD | 3.52% |
| 2021 Q4 | 1.95 Billion USD | -4.99% |
| 2021 Q1 | 2.16 Billion USD | 12.94% |
| 2021 FY | 1.95 Billion USD | 1.81% |
| 2021 Q2 | 1.98 Billion USD | -8.35% |
| 2020 FY | 1.91 Billion USD | 35.4% |
| 2020 Q4 | 1.91 Billion USD | 6.38% |
| 2020 Q1 | 1.48 Billion USD | 4.62% |
| 2020 Q2 | 1.64 Billion USD | 10.8% |
| 2020 Q3 | 1.8 Billion USD | 9.79% |
| 2019 Q3 | 1.34 Billion USD | 2.06% |
| 2019 Q4 | 1.41 Billion USD | 5.3% |
| 2019 Q2 | 1.31 Billion USD | 8.97% |
| 2019 Q1 | 1.2 Billion USD | 5.0% |
| 2019 FY | 1.41 Billion USD | 22.96% |
| 2018 Q3 | 1.03 Billion USD | 11.97% |
| 2018 Q1 | 820.39 Million USD | 12.98% |
| 2018 FY | 1.15 Billion USD | 58.54% |
| 2018 Q2 | 928.55 Million USD | 13.18% |
| 2018 Q4 | 1.15 Billion USD | 10.73% |
| 2017 FY | 726.13 Million USD | 81.83% |
| 2017 Q3 | 641.58 Million USD | 15.74% |
| 2017 Q4 | 726.13 Million USD | 13.18% |
| 2017 Q1 | 466.57 Million USD | 16.83% |
| 2017 Q2 | 554.32 Million USD | 18.81% |
| 2016 Q4 | 399.35 Million USD | 15.55% |
| 2016 FY | 399.35 Million USD | 67.39% |
| 2016 Q2 | 316.07 Million USD | 4.21% |
| 2016 Q3 | 345.62 Million USD | 9.35% |
| 2016 Q1 | 303.29 Million USD | 27.13% |
| 2015 Q2 | 171.26 Million USD | 27.94% |
| 2015 Q1 | 133.86 Million USD | 3.88% |
| 2015 Q4 | 238.57 Million USD | 25.13% |
| 2015 Q3 | 190.66 Million USD | 11.33% |
| 2015 FY | 238.57 Million USD | 85.14% |
| 2014 Q4 | 128.86 Million USD | 7.1% |
| 2014 FY | 128.86 Million USD | 83.16% |
| 2014 Q1 | 86.54 Million USD | 23.01% |
| 2014 Q2 | 109.89 Million USD | 26.98% |
| 2014 Q3 | 120.31 Million USD | 9.48% |
| 2013 Q3 | 63.29 Million USD | 10.73% |
| 2013 Q2 | 57.15 Million USD | 29.97% |
| 2013 Q1 | 43.97 Million USD | 53.56% |
| 2013 FY | 70.35 Million USD | 145.67% |
| 2013 Q4 | 70.35 Million USD | 11.16% |
| 2012 Q4 | 28.63 Million USD | -3.15% |
| 2012 Q2 | 24.42 Million USD | 18.47% |
| 2012 Q1 | 20.61 Million USD | 52.09% |
| 2012 FY | 28.63 Million USD | 111.26% |
| 2012 Q3 | 29.57 Million USD | 21.06% |
| 2011 Q1 | -226.44 Million USD | -1395.45% |
| 2011 Q4 | 13.55 Million USD | 0.0% |
| 2011 FY | 13.55 Million USD | 189.53% |
| 2011 Q2 | - USD | 100.0% |
| 2011 Q3 | - USD | 0.0% |
| 2010 Q1 | - USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 Q4 | -15.14 Million USD | 0.0% |
| 2010 FY | -15.14 Million USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2009 Q3 | - USD | 100.0% |
| 2009 FY | - USD | 0.0% |
| 2009 Q2 | -391.91 Million USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2007 Q1 | - USD | 0.0% |
| 2006 Q3 | - USD | -100.0% |
| 2006 Q1 | 3.25 Million USD | 12.05% |
| 2006 FY | - USD | -100.0% |
| 2006 Q2 | 2.12 Million USD | -34.6% |
| 2006 Q4 | - USD | 0.0% |
| 2005 Q4 | 2.9 Million USD | 2.36% |
| 2005 Q3 | 2.83 Million USD | -24.27% |
| 2005 Q2 | 3.74 Million USD | 21.35% |
| 2005 Q1 | 3.08 Million USD | -4.4% |
| 2005 FY | 2.9 Million USD | -10.07% |
| 2004 Q3 | 4.26 Million USD | -60.68% |
| 2004 Q2 | 10.85 Million USD | 19.26% |
| 2004 FY | 3.22 Million USD | -64.15% |
| 2004 Q4 | 3.22 Million USD | -24.31% |
| 2004 Q1 | 9.09 Million USD | 1.02% |
| 2003 Q2 | 10.34 Million USD | 22.58% |
| 2003 FY | 9 Million USD | 31.84% |
| 2003 Q4 | 9 Million USD | 16.99% |
| 2003 Q3 | 7.69 Million USD | -25.57% |
| 2003 Q1 | 8.43 Million USD | 23.51% |
| 2002 Q3 | 6.15 Million USD | 14.67% |
| 2002 Q4 | 6.83 Million USD | 11.04% |
| 2002 Q1 | 4.98 Million USD | 25.57% |
| 2002 Q2 | 5.36 Million USD | 7.54% |
| 2002 FY | 6.83 Million USD | 71.94% |
| 2001 Q4 | 3.97 Million USD | 30.01% |
| 2001 FY | 3.97 Million USD | 107.47% |
| 2001 Q1 | 2.66 Million USD | 39.32% |
| 2001 Q2 | 2.26 Million USD | -15.18% |
| 2001 Q3 | 3.05 Million USD | 35.04% |
| 2000 FY | 1.91 Million USD | -58.37% |
| 2000 Q1 | 5.64 Million USD | 22.63% |
| 2000 Q3 | 8.18 Million USD | 3.15% |
| 2000 Q2 | 7.93 Million USD | 40.6% |
| 2000 Q4 | 1.91 Million USD | -76.59% |
| 1999 Q1 | - USD | 0.0% |
| 1999 FY | 4.6 Million USD | 0.0% |
| 1999 Q3 | - USD | 0.0% |
| 1999 Q2 | - USD | 0.0% |
| 1999 Q4 | 4.6 Million USD | 0.0% |
| 1998 Q1 | - USD | 0.0% |
| 1998 Q2 | - USD | 0.0% |
| 1998 Q3 | - USD | 0.0% |
| 1998 Q4 | - USD | 0.0% |
| 1998 FY | - USD | 0.0% |
| 1997 Q1 | - USD | 0.0% |
| 1997 FY | - USD | 0.0% |
| 1997 Q3 | - USD | 0.0% |
| 1997 Q4 | - USD | 0.0% |
| 1997 Q2 | - USD | 0.0% |
| 1996 Q1 | - USD | 0.0% |
| 1996 Q4 | - USD | 0.0% |
| 1996 Q3 | - USD | 0.0% |
| 1996 FY | - USD | 0.0% |
| 1996 Q2 | - USD | 0.0% |
| 1995 Q1 | - USD | 0.0% |
| 1995 Q3 | - USD | 0.0% |
| 1995 Q4 | - USD | 0.0% |
| 1995 Q2 | - USD | 0.0% |
| 1995 FY | - USD | 0.0% |
| 1994 Q2 | - USD | 0.0% |
| 1994 Q1 | - USD | 0.0% |
| 1994 FY | - USD | 0.0% |
| 1994 Q4 | - USD | 0.0% |
| 1994 Q3 | - USD | 0.0% |
| 1993 Q3 | - USD | 0.0% |
| 1993 FY | - USD | 0.0% |
| 1993 Q2 | - USD | 0.0% |
| 1993 Q1 | - USD | 0.0% |
| 1993 Q4 | - USD | 0.0% |
| 1992 Q4 | - USD | 0.0% |
| 1992 Q3 | - USD | 0.0% |
| 1992 Q2 | - USD | 0.0% |
| 1992 Q1 | - USD | 0.0% |
| 1992 FY | - USD | 0.0% |
| 1991 Q3 | - USD | 0.0% |
| 1991 FY | - USD | 0.0% |
| 1991 Q2 | - USD | 0.0% |
| 1991 Q4 | - USD | 0.0% |
| 1990 Q4 | - USD | 0.0% |
| 1990 FY | - USD | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| uniQure N.V. | 12.02 Million USD | -21361.244% |
| Agios Pharmaceuticals, Inc. | 19.07 Million USD | -13427.469% |
| Amicus Therapeutics, Inc. | 59.69 Million USD | -4222.735% |
| Atara Biotherapeutics, Inc. | 9.7 Million USD | -26486.647% |
| bluebird bio, Inc. | 22.91 Million USD | -11159.217% |
| Cara Therapeutics, Inc. | 2.82 Million USD | -91374.654% |
| Imunon, Inc. | - USD | -Infinity% |
| Editas Medicine, Inc. | - USD | -Infinity% |
| IQVIA Holdings Inc. | - USD | -Infinity% |
| Mettler-Toledo International Inc. | 385.86 Million USD | -568.757% |
| Myriad Genetics, Inc. | 20.1 Million USD | -12738.308% |
| Neurocrine Biosciences, Inc. | 38.3 Million USD | -6637.598% |
| Supernus Pharmaceuticals, Inc. | 77.4 Million USD | -3233.635% |
| Verastem, Inc. | - USD | -Infinity% |
| Walgreens Boots Alliance, Inc. | 8.32 Billion USD | 68.984% |
| Waters Corporation | 516.23 Million USD | -399.868% |
| Thermo Fisher Scientific Inc. | 5.08 Billion USD | 49.283% |
| Biogen Inc. | 2.52 Billion USD | -2.101% |
| Nektar Therapeutics | 16.1 Million USD | -15926.955% |
| Perrigo Company plc | 1.14 Billion USD | -126.181% |
| Dynavax Technologies Corporation | 53.29 Million USD | -4742.372% |
| Illumina, Inc. | 587 Million USD | -339.608% |
| Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Iovance Biotherapeutics, Inc. | 10.37 Million USD | -24779.483% |
| Heron Therapeutics, Inc. | 42.11 Million USD | -6027.998% |
| Unity Biotechnology, Inc. | - USD | -Infinity% |
| BioMarin Pharmaceutical Inc. | 1.1 Billion USD | -133.069% |
| Sangamo Therapeutics, Inc. | - USD | -Infinity% |
| Evolus, Inc. | 10.99 Million USD | -23363.357% |
| Adicet Bio, Inc. | - USD | -Infinity% |
| Aclaris Therapeutics, Inc. | - USD | -Infinity% |
| Esperion Therapeutics, Inc. | 65.62 Million USD | -3832.31% |
| FibroGen, Inc. | 41.56 Million USD | -6108.348% |
| Agilent Technologies, Inc. | 1.03 Billion USD | -150.291% |
| OPKO Health, Inc. | 65.69 Million USD | -3827.881% |
| Homology Medicines, Inc. | - USD | -Infinity% |
| Geron Corporation | - USD | -Infinity% |
| Alnylam Pharmaceuticals, Inc. | 89.14 Million USD | -2794.69% |
| Exelixis, Inc. | 17.32 Million USD | -14796.381% |
| Viking Therapeutics, Inc. | - USD | -Infinity% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | - USD | -Infinity% |
| Zoetis Inc. | 2.56 Billion USD | -0.644% |
| Axsome Therapeutics, Inc. | 15.13 Million USD | -16949.884% |
| Abeona Therapeutics Inc. | -2.44 Million USD | 105685.106% |
| Vertex Pharmaceuticals Incorporated | 738.8 Million USD | -249.283% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Ionis Pharmaceuticals, Inc. | 28.42 Million USD | -8978.276% |
| Sarepta Therapeutics, Inc. | 322.85 Million USD | -699.265% |
| Corcept Therapeutics Incorporated | 7.73 Million USD | -33282.924% |
| Halozyme Therapeutics, Inc. | 127.6 Million USD | -1922.32% |
| Blueprint Medicines Corporation | 21.22 Million USD | -12058.978% |
| Insmed Incorporated | 83.24 Million USD | -2999.774% |
| TG Therapeutics, Inc. | 39.82 Million USD | -6379.924% |
| Incyte Corporation | 62.97 Million USD | -3997.853% |
| Emergent BioSolutions Inc. | 328.9 Million USD | -684.585% |